The stock of Egalet Corp (NASDAQ:EGLT) is a huge mover today! About 322,805 shares traded hands. Egalet Corp (NASDAQ:EGLT) has declined 28.86% since April 4, 2016 and is downtrending. It has underperformed by 29.95% the S&P500.
The move comes after 8 months positive chart setup for the $131.93M company. It was reported on Nov, 4 by Barchart.com. We have $9.04 PT which if reached, will make NASDAQ:EGLT worth $89.71M more.
According to Zacks Investment Research, “Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in the developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and in other indications. Its principal product candidate consist of Egalet-001, is an abuse-deterrent, extended-release, oral morphine formulation in development for the treatment of moderate to severe pain, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation in development for the treatment of moderate to severe pain and Egalet-003 which are in pre-clinical trials. Egalet Corporation is based in City of Westminster, United Kingdom.”
Insitutional Activity: The institutional sentiment decreased to 1.79 in Q2 2016. Its down 0.13, from 1.92 in 2016Q1. The ratio worsened, as 9 funds sold all Egalet Corp shares owned while 10 reduced positions. 16 funds bought stakes while 18 increased positions. They now own 13.97 million shares or 0.03% less from 13.98 million shares in 2016Q1.
Vanguard has 0% invested in the company for 461,128 shares. Blackrock Advisors Ltd Com holds 6,453 shares or 0% of its portfolio. Rock Springs Cap Management L P last reported 300,000 shares in the company. Nationwide Fund Advisors, a Pennsylvania-based fund reported 18,787 shares. Citigroup Inc last reported 0% of its portfolio in the stock. Jacobs Levy Equity, a New Jersey-based fund reported 61,596 shares. Federated Pa last reported 0.02% of its portfolio in the stock. Eagle Global Advsr Ltd Company holds 10,820 shares or 0% of its portfolio. Blackrock Institutional Tru Na has 0% invested in the company for 240,175 shares. Schwab Charles Invest last reported 35,600 shares in the company. Keybank National Association Oh holds 29,291 shares or 0% of its portfolio. State Bank Of New York Mellon has 0% invested in the company for 54,334 shares. Broadfin Cap Limited Company holds 1.13 million shares or 0.55% of its portfolio. Geode Management Ltd Liability accumulated 80,957 shares or 0% of the stock. Sphera Funds Management Limited has 292,500 shares for 0.38% of their US portfolio.
More important recent Egalet Corp (NASDAQ:EGLT) news were published by: Streetinsider.com which released: “Form 8-K Egalet Corp For: Nov 04” on November 04, 2016, also Philly.com published article titled: “Delay in approval of Egalet Corp’s abuse-deterrent opioid medicine”, Prnewswire.com published: “Egalet Notified that FDA Will Not Meet PDUFA Goal Date for ARYMO ER” on October 13, 2016. More interesting news about Egalet Corp (NASDAQ:EGLT) was released by: Prnewswire.com and their article: “Egalet Completes $40 Million Secured Debt Financing” with publication date: August 31, 2016.
EGLT Company Profile
Egalet Corporation, incorporated on August 21, 2013, is a specialty pharmaceutical company. The Firm is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Firm is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company’s Guardian Technology is a polymer matrix tablet technology that utilizes a manufacturing process, injection molding, which results in tablets with controlled-release properties, as well as physical and chemical features that have been demonstrated to resist both common and rigorous methods of manipulation. The Company’s Guardian Technology can be used to create tablets. The Company’s Guardian Technology platform, which combines abuse-deterrent features and precision delivery, is applied across various classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients (APIs) with similar or different release profiles.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.